[go: up one dir, main page]

TW200611689A - Cancer chemotherapy - Google Patents

Cancer chemotherapy

Info

Publication number
TW200611689A
TW200611689A TW094120644A TW94120644A TW200611689A TW 200611689 A TW200611689 A TW 200611689A TW 094120644 A TW094120644 A TW 094120644A TW 94120644 A TW94120644 A TW 94120644A TW 200611689 A TW200611689 A TW 200611689A
Authority
TW
Taiwan
Prior art keywords
cancer chemotherapy
effective amount
cancer
administering
subject
Prior art date
Application number
TW094120644A
Other languages
English (en)
Inventor
xiao-qiang Yan
yu-min Cui
wei-han Zhang
Jian Zuo
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of TW200611689A publication Critical patent/TW200611689A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094120644A 2004-06-21 2005-06-21 Cancer chemotherapy TW200611689A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58166304P 2004-06-21 2004-06-21
US63423804P 2004-12-07 2004-12-07

Publications (1)

Publication Number Publication Date
TW200611689A true TW200611689A (en) 2006-04-16

Family

ID=35785716

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094120644A TW200611689A (en) 2004-06-21 2005-06-21 Cancer chemotherapy

Country Status (9)

Country Link
US (1) US20050288378A1 (zh)
EP (1) EP1784172A4 (zh)
JP (1) JP2008503579A (zh)
KR (1) KR20070032795A (zh)
AU (1) AU2005265155A1 (zh)
CA (1) CA2571457A1 (zh)
RU (1) RU2007102086A (zh)
TW (1) TW200611689A (zh)
WO (1) WO2006009893A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257410B2 (en) * 2006-02-03 2012-09-04 The Catholic University Of America Use of weak stressors to enhance the effectiveness of ionizing radiation and other treatments of disease
CA2717741C (en) * 2008-03-05 2018-04-03 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
US10519504B2 (en) * 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US11400058B2 (en) 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
GB201213486D0 (en) * 2012-07-30 2012-09-12 Univ Salford The Quinone compounds and their uses for the treatment of cancer
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185316A (en) * 1989-11-07 1993-02-09 Dai Nippon Insatsu Kabushiki Kaisha Heat transfer image-receiving sheets
FR2673625B1 (fr) * 1991-03-08 1993-05-07 Adir Nouveaux derives d'acylaminophenol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US6558712B1 (en) * 2001-09-21 2003-05-06 Natreon Inc. Delivery system for pharmaceutical, nutritional and cosmetic ingredients
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
ES2631152T3 (es) * 2004-01-22 2017-08-28 University Of Miami Formulaciones de coenzima Q10 tópicas o intravenosas para su uso en el tratamiento del cáncer
WO2006009840A1 (en) * 2004-06-21 2006-01-26 Hutchison Medipharma Enterprises Limited Benzoquinone compounds as a anti-cancer agents

Also Published As

Publication number Publication date
RU2007102086A (ru) 2008-07-27
EP1784172A4 (en) 2007-12-19
JP2008503579A (ja) 2008-02-07
CA2571457A1 (en) 2006-01-26
AU2005265155A1 (en) 2006-01-26
WO2006009893A2 (en) 2006-01-26
EP1784172A2 (en) 2007-05-16
WO2006009893A3 (en) 2006-12-21
US20050288378A1 (en) 2005-12-29
KR20070032795A (ko) 2007-03-22

Similar Documents

Publication Publication Date Title
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2007106192A3 (en) Inhibitors of iap
MY184464A (en) Combined use of cholestanol derivative
WO2006113942A3 (en) Method of inhibiting cathepsin activity
TW200744586A (en) Therapeutic compounds
PH12012501351A1 (en) Synthesis of eporthilones, intermediates thereto, analogues and uses thereof
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
IL183514A0 (en) Pyrrolidine inhibitors of iap
MY142988A (en) Novel aminobenzophenone compounds
MX2007002816A (es) Metodos para tratar un trastorno.
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
IN2012DN02609A (zh)
WO2006001967A3 (en) Migrastatin analogs in the treatment of cancer
TW200611689A (en) Cancer chemotherapy
ZA200901921B (en) Pyrazolopyrimidine derivative
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.
AU2003300385A8 (en) Anticancer compounds
TW200637561A (en) Antitumor agent
TW200700071A (en) Novel use
MX2010001303A (es) Compuestos terapeuticos.
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
WO2005084222A3 (en) Synthesis of epothilones, intermediates thereto, analogues and uses thereof
TW200602027A (en) Benzoquinone compounds as anti-cancer agents